Promoting Cardiovascular Stability: Blood Transfusions in the Management of HIV-Related Complications

Article · September 2024

CITATIONS
0

READS
6

2 authors:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS
SEE PROFILE

Getrude Uzoma Obeagu
Kampala International University
649 PUBLICATIONS **18,724** CITATIONS
SEE PROFILE

Elite Journal of Health Sciences. Volume 2 Issue 9(2024), Pp. 9-17

https://epjournals.com/journals/EJHS

Promoting Cardiovascular Stability: Blood Transfusions in the Management of HIV-Related Complications

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Blood transfusions are increasingly recognized for their role in promoting cardiovascular stability in HIV patients, addressing complications such as anemia and associated cardiovascular issues. This review examines the multifaceted mechanisms through which blood transfusions contribute to cardiovascular health in the context of HIV. By correcting anemia, transfusions enhance oxygen delivery, reduce cardiovascular strain, and improve overall cardiovascular function. Additionally, transfusions support endothelial function and help mitigate some of the cardiovascular side effects associated with antiretroviral therapy (ART). HIV-related cardiovascular complications, including anemia and increased risk of myocardial infarction and stroke, necessitate a comprehensive approach to management. Blood transfusions play a crucial role in alleviating these issues by improving hemoglobin levels, reducing the burden on the heart, and supporting endothelial health. This review highlights how transfusions not only address the immediate effects of anemia but also contribute to long-term cardiovascular stability.

Keywords: *Cardiovascular Stability, Blood Transfusions, Management, HIV*

Introduction

HIV infection is associated with a spectrum of complications that impact multiple organ systems, with cardiovascular health being a particularly significant concern. Cardiovascular complications in HIV patients can arise from the direct effects of the virus, the side effects of antiretroviral

Citation: Obeagu EI, Obeagu GU. Promoting Cardiovascular Stability: Blood Transfusions in the Management of HIV-Related Complications. Elite Journal of Health Science, 2024; 2(9): 9-17

therapy (ART), and the chronic inflammatory state induced by the infection. Among these complications, anemia is a prevalent issue that exacerbates cardiovascular strain and contributes to poor health outcomes. Blood transfusions have long been employed to manage anemia; however, their role extends beyond this primary function to support overall cardiovascular stability and health.[1-3] Anemia in HIV-infected individuals often results from the direct impact of the virus on hematopoiesis, opportunistic infections, or as a side effect of ART. This condition reduces the number of red blood cells and hemoglobin levels, impairing oxygen delivery to tissues and increasing cardiovascular workload. Blood transfusions effectively address anemia by replenishing red blood cells and improving oxygen transport, thereby alleviating symptoms such as fatigue and weakness. This correction of anemia directly reduces the cardiovascular strain placed on the heart and circulatory system, enhancing overall cardiovascular function.[4-6] The relationship between HIV, anemia, and cardiovascular health is complex, with anemia contributing to increased cardiovascular risk and adverse outcomes. HIV patients with anemia may experience heightened risks of myocardial infarction, stroke, and other cardiovascular events. By improving hemoglobin levels, blood transfusions help to mitigate these risks by reducing the heart's workload and improving oxygen delivery to vital organs. This improvement in cardiovascular stability is critical for enhancing patient outcomes and managing the broader implications of HIV-related complications.[7-9]

Antiretroviral therapy (ART) has revolutionized HIV management but is not without its cardiovascular effects. Certain ART regimens are associated with dyslipidemia, insulin resistance, and endothelial dysfunction, which can exacerbate cardiovascular risk. Blood transfusions can play a supportive role in managing these ART-related cardiovascular effects by improving overall blood quality and reducing the cardiovascular burden. This supportive role highlights the importance of integrating transfusions into comprehensive HIV care to address both hematologic and cardiovascular concerns.[10-12] Endothelial dysfunction is another critical aspect of cardiovascular health in HIV patients. Chronic inflammation and oxidative stress associated with HIV infection can impair endothelial function, increasing the risk of vascular events. Blood transfusions can positively influence endothelial health by improving oxygenation and reducing inflammatory markers. This supportive effect on endothelial function contributes to overall cardiovascular stability and helps manage the risks associated with HIV-related endothelial dysfunction.[13-15] Integrating blood transfusions into comprehensive HIV care requires a coordinated approach involving various healthcare professionals, including HIV specialists, cardiologists, and transfusion medicine experts. This multidisciplinary collaboration ensures that transfusions are used effectively to address both anemia and associated cardiovascular issues. Regular monitoring and personalized treatment plans are essential to optimize the benefits of transfusions and manage potential risks, such as transfusion reactions and iron overload.[16-18]

Mechanisms of Blood Transfusions in Supporting Cardiovascular Stability

Correction of Anemia and Improved Oxygenation: The primary mechanism through which blood transfusions support cardiovascular stability is the correction of anemia. In HIV patients, anemia can result from various factors, including the direct effects of the virus, opportunistic infections,

or side effects of antiretroviral therapy (ART). Anemia reduces the number of red blood cells and hemoglobin, impairing oxygen delivery to tissues and placing additional strain on the cardiovascular system. Blood transfusions address this issue by increasing the levels of red blood cells and hemoglobin, thereby improving oxygen transport throughout the body. This enhancement in oxygenation reduces the workload on the heart, alleviates symptoms such as fatigue and weakness, and contributes to overall cardiovascular stability.[19-21] By improving hemoglobin levels and oxygen delivery, blood transfusions effectively reduce cardiovascular strain. In individuals with anemia, the heart must work harder to pump oxygenated blood to tissues, which can exacerbate cardiovascular conditions and lead to complications such as heart failure. Transfusions decrease the heart's workload by alleviating anemia, allowing the cardiovascular system to function more efficiently. This reduction in strain is particularly beneficial for HIV patients who may already be at increased risk of cardiovascular issues due to chronic inflammation and ART-related side effects. Endothelial dysfunction is a significant concern in HIV patients, often resulting from chronic inflammation and oxidative stress. The endothelium, the inner lining of blood vessels, plays a crucial role in maintaining vascular health and regulating blood flow. Blood transfusions can positively impact endothelial function by improving overall blood quality and reducing inflammatory markers. Enhanced oxygenation and reduced oxidative stress contribute to healthier endothelial cells, which in turn support better vascular function and reduce the risk of cardiovascular events.[22-25]

Certain ART regimens are associated with adverse cardiovascular effects, including dyslipidemia, insulin resistance, and endothelial dysfunction. Blood transfusions can help mitigate some of these effects by improving overall blood quality and supporting cardiovascular health. For example, improved oxygenation from transfusions can help counteract the cardiovascular strain imposed by ART-related dyslipidemia. By addressing anemia and its impacts, transfusions provide additional support to manage the broader cardiovascular consequences of ART. Effective cardiovascular function is closely linked to systemic metabolism, including the delivery of nutrients and oxygen to tissues. Blood transfusions enhance systemic metabolism by improving oxygenation and supporting metabolic processes. This improvement in metabolism benefits cardiovascular health by ensuring that tissues receive adequate oxygen and nutrients, reducing the risk of ischemic events and supporting overall cardiovascular stability.[26-29] In HIV patients with cardiovascular complications, symptoms such as chest pain, shortness of breath, and fatigue can be exacerbated by anemia. Blood transfusions address these symptoms by correcting anemia and improving overall cardiovascular function. By alleviating symptoms and improving quality of life, transfusions contribute to better management of cardiovascular complications and support overall patient well-being. While the immediate benefits of blood transfusions for cardiovascular stability are well-documented, their potential role in long-term cardiovascular health is an area of ongoing research.[30-31]

Integration into Comprehensive HIV Care

Integrating blood transfusions into comprehensive HIV care requires a coordinated effort from a multidisciplinary team. This team typically includes HIV specialists, cardiologists, hematologists,

and transfusion medicine experts. Each specialist plays a crucial role in managing different aspects of the patient's care. HIV specialists oversee the overall treatment of the infection, cardiologists address cardiovascular health, hematologists manage blood disorders, and transfusion medicine experts ensure the safe and effective administration of transfusions. Collaboration among these professionals is essential for creating a holistic treatment plan that addresses both HIV and its related complications.[32-34] Personalizing treatment plans is a cornerstone of integrating blood transfusions into HIV care. Each patient presents unique challenges and health needs, making individualized care critical. For instance, a patient with severe anemia due to HIV-related complications may require a specific transfusion protocol tailored to their condition. Additionally, personalized plans must consider the patient's overall health, existing comorbidities, and response to previous treatments. By tailoring transfusions and other interventions to the patient's specific needs, healthcare providers can optimize treatment outcomes and support cardiovascular stability effectively.[35-36] Ongoing monitoring and assessment are vital for integrating blood transfusions into HIV care. Regular evaluations of hemoglobin levels, cardiovascular health, and overall response to transfusions help ensure that the therapy is effective and safe. Monitoring should include routine blood tests, cardiovascular assessments, and evaluations of potential transfusion-related complications. This continuous oversight allows healthcare providers to adjust treatment plans as needed, address any emerging issues promptly, and ensure that transfusions are contributing positively to the patient's health and well-being.[37]

Effective integration of blood transfusions into HIV care involves careful management of potential risks and complications. Blood transfusions carry risks such as transfusion reactions, infection transmission, and iron overload. Implementing stringent safety protocols, including thorough donor screening, proper blood handling, and vigilant monitoring during and after transfusions, is crucial to minimizing these risks. Educating patients about potential side effects and the importance of reporting any adverse reactions promptly also helps ensure the safe use of transfusions.[38] ART is a cornerstone of HIV treatment but can have cardiovascular side effects that impact overall health. Integrating blood transfusions into care plans involves addressing these ART-related complications alongside managing anemia. For example, ART-related dyslipidemia may necessitate adjustments in transfusion protocols or additional treatments to support cardiovascular health. By considering the interplay between ART and transfusions, healthcare providers can develop more comprehensive strategies to manage both HIV and its associated complications effectively.[39] Patient education and support are critical components of integrating blood transfusions into HIV care. Patients need to understand the purpose of transfusions, the potential benefits and risks, and the importance of adherence to treatment plans. Providing clear information about how transfusions can improve cardiovascular stability and overall health helps patients make informed decisions and engage actively in their care. Support services, including counseling and peer support groups, can also play a role in helping patients cope with the emotional and psychological aspects of managing chronic illness and undergoing transfusions.[40]

Benefits

Improvement in Anemia and Oxygenation: Blood transfusions provide a direct and effective solution for anemia, a common and debilitating complication in HIV patients. By increasing red blood cell count and hemoglobin levels, transfusions enhance oxygen delivery to tissues, thereby alleviating symptoms such as fatigue, weakness, and shortness of breath. This improvement in oxygenation helps reduce cardiovascular strain, supports overall physical health, and contributes to better quality of life. By addressing anemia, blood transfusions reduce the additional workload placed on the heart and circulatory system. This reduction in cardiovascular strain is crucial for HIV patients who may already be at increased risk of cardiovascular complications. Enhanced oxygen delivery through transfusions allows the heart to function more efficiently, potentially reducing the risk of heart failure and other cardiovascular issues.[41] Transfusions can positively impact endothelial function by improving blood quality and reducing inflammation. Healthy endothelial cells are essential for maintaining vascular health and regulating blood flow. By reducing inflammatory markers and oxidative stress, transfusions help support endothelial health, which can mitigate the risk of vascular events such as stroke and myocardial infarction. Certain ART regimens are associated with cardiovascular side effects, including dyslipidemia and insulin resistance. Blood transfusions can help mitigate some of these effects by improving overall blood quality and reducing cardiovascular burden. This supportive role is beneficial in managing the broader cardiovascular implications of ART, enhancing overall patient health and stability. Patients experiencing severe anemia often face significant health challenges, including reduced exercise capacity, diminished cognitive function, and lower overall well-being. By improving hemoglobin levels and alleviating anemia-related symptoms, blood transfusions contribute to a better quality of life, allowing patients to engage more fully in daily activities and improve their overall health status.[42]

Risks:

One of the primary risks associated with blood transfusions is the potential for transfusion reactions, including allergic reactions, febrile non-hemolytic reactions, and more severe complications such as hemolytic reactions. These reactions can range from mild to life-threatening and require careful monitoring and management during and after transfusion. Although the risk is significantly reduced due to rigorous screening and testing, there is still a minimal risk of transmitting infections through blood transfusions. Potential infections include viral, bacterial, and parasitic pathogens. Ensuring stringent donor screening and blood testing protocols helps minimize this risk. Repeated blood transfusions can lead to iron overload, also known as secondary hemochromatosis. Excess iron deposits in various organs, such as the heart and liver, can cause damage and dysfunction. Monitoring iron levels and implementing chelation therapy, if necessary, are important to manage and mitigate this risk.[43] Transfusion-Related Acute Lung Injury (TRALI) is a rare but serious condition characterized by acute lung injury occurring shortly after a transfusion. It is thought to result from antibodies in the transfused blood reacting with the recipient's white blood cells, leading to pulmonary inflammation and respiratory distress. Prompt recognition and management are essential to address this complication. Repeated blood transfusions can lead to alloimmunization, where the patient's immune system develops antibodies against transfused blood components. This can complicate future transfusions and make it

challenging to find compatible blood. Careful management and monitoring are required to address and prevent alloimmunization. The use of blood transfusions involves significant healthcare resources and costs, including blood collection, testing, processing, and administration. While transfusions are essential for managing anemia and related complications, their use must be balanced with cost considerations and the availability of blood products.[43]

Conclusion

Blood transfusions play a pivotal role in the comprehensive management of HIV-related complications, particularly in promoting cardiovascular stability. The primary benefit of transfusions lies in their ability to correct anemia, thereby enhancing oxygenation, reducing cardiovascular strain, and improving overall physical health. By addressing anemia, transfusions contribute to a reduction in the heart's workload, support endothelial function, and mitigate some of the cardiovascular side effects associated with antiretroviral therapy (ART). These benefits collectively enhance the quality of life for HIV patients, allowing them to engage more fully in daily activities and manage their condition more effectively. Despite these advantages, the integration of blood transfusions into HIV care involves careful consideration of associated risks, including transfusion reactions, infection transmission, iron overload, and alloimmunization. Effective management of these risks requires stringent safety protocols, regular monitoring, and personalized treatment plans tailored to the individual needs of each patient. A multidisciplinary approach, involving HIV specialists, cardiologists, hematologists, and transfusion medicine experts, is crucial for optimizing the use of transfusions and ensuring safe and effective care.

References

1. Ezeamama AE, Sikorskii A, Bajwa RK, Tuke R, Kyeyune RB, Fenton JI, Guwatudde D, Fawzi WW. Evolution of anemia types during antiretroviral therapy—implications for treatment outcomes and quality of life among HIV-infected adults. Nutrients. 2019;11(4):755.
2. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
4. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
5. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. Journal of Public Health and Nutrition. 2023;6(1):138.

Citation: Obeagu EI, Obeagu GU. Promoting Cardiovascular Stability: Blood Transfusions in the Management of HIV-Related Complications. Elite Journal of Health Science, 2024; 2(9): 9-17

7. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
8. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
9. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.
10. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
11. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
12. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
13. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
14. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
15. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
16. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.
17. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. Frontiers in Medicine. 2022; 9:903739.
18. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
19. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
20. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16
21. Kuldanek SA, Kelher M, Silliman CC. Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update. Expert review of hematology. 2019;12(9):773-785.
22. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical infectious diseases. 2004;38(10):1454-1463.

Citation: Obeagu EI, Obeagu GU. Promoting Cardiovascular Stability: Blood Transfusions in the Management of HIV-Related Complications. Elite Journal of Health Science, 2024; 2(9): 9-17

23. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology. 2024;2(3):42-57.
24. Obeagu EI. The Impact of Howell-Jolly Bodies on Quality of Life in HIV Patients: A Review. Elite Journal of Public Health. 2024;2(5):32-42.
25. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.
26. Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, Stevens W, Jani I, Abimiku AL, Ford N, Katz Z. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. The Lancet Infectious Diseases. 2017 ;17(1):e26-9.
27. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
28. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. Elite Journal of Haematology, 2024; 2 (4). 2024:51-67.
29. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR. 2004;53(RR15):1-12.
30. Dikshit B, Wanchu A, Sachdeva RK, Sharma A, Das R. Profile of hematological abnormalities of Indian HIV infected individuals. BMC hematology. 2009; 9:1-6.
31. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus—infected patients. The Journal of infectious diseases. 2002;185(Supplement_2):S110-4.
32. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024;103(2):e36937.
33. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical infectious diseases. 2004;38(10):1454-1463.
34. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
35. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
36. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
37. Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA. 2001;285(12):1592-601.
38. Obeagu EI. Hematological Consequences of Erythropoietin in HIV: Clinical Implications. Elite Journal of Laboratory Medicine. 2024;2(6):1-9.

39. Muñoz M, Breymann C, García-Erce JA, Gómez-Ramírez S, Comin J, Bisbe E. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox sanguinis. 2008;94(3):172-183.
40. Gould SA, Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World journal of surgery. 1996 Nov;20(9):1200-1207.
41. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ, Viral Activation Transfusion Study Investigators*. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of internal medicine. 2001;135(1):17-26.
42. Wiciński M, Liczner G, Cadelski K, Kołnierzak T, Nowaczewska M, Malinowski B. Anemia of chronic diseases: wider diagnostics—better treatment? Nutrients. 2020;12(6):1784.
43. Desai N, Schofield N, Richards T. Perioperative patient blood management to improve outcomes. Anesthesia & Analgesia. 2018;127(5):1211-1220.